News

Oxilio Limited (“Oxilio”) reports favourable safety and pharmacokinetic data from a single-part, five-period, sequential, open-labelled Phase 1 study of OXL001 in healthy male volunteers that is being conducted at Quotient Sciences.

Quotient Sciences' Nand Singh featured in BJCP's article on 'Evaluation of the drug disposition of RO7049389 with in vitro data and human mass balance supported by physiologically based pharmacokinetic modeling'.

Eleanor Row discusses the challenges and considerations that drug developers should be aware of when quickly advancing their molecules from discovery to the investigational new drug (IND) stage and onward into the clinic, while emphasizing the benefits of an integrated approach to accelerate the process.

Quotient Sciences’ Executive Director of Commercial, Eleanor Row, offers her thought leadership in Contract Pharma on the 3 key trends shaping our industry.

During DCAT Week 2023, Sarah Stevens, senior vice-president and head of Drug Product Development & Manufacturing at Quotient Sciences, discussed various facets of the modern pharmaceutical outsourcing industry with Grant Playter, associate editor of Pharm Tech.

Quotient Sciences has supported Evecxia with the Phase 1 two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram. Favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data was announced from the study.